Frequently asked questions
Is Honasa Consumer a buy at current prices?
DalalBytes rates Honasa Consumer Positive at 75/100, after the Project Neev crisis: Q1 FY27 revenue of Rs 756 crore (+27%), 14.1% EBITDA margins, zero debt, and Rs 1,100 crore of cash. Risks: Mamaearth is about 58% of revenue and HUL's Minimalist acquisition aims 9 million outlets at The Derma Co. At 16% below the 52-week high, risk-reward favors the proven business.
What are Honasa's FY2029 price targets?
DalalBytes' FY2029 targets for Honasa are bear Rs 310, base Rs 565, and bull Rs 890, from a Rs 427.90 reference price. Bear: 12% CAGR, 9% EBITDA margin, 30x exit. Base: 18% CAGR, 11.5% margin, 38x. Bull: 24% CAGR, 13.5% margin, 45x. The base case implies about Rs 11 of FY29 EPS.
What is the verdict on Honasa Consumer?
Honasa Consumer is the rare Indian D2C story that survived its own crisis and came out stronger. Four straight quarters of 20%+ growth, EBITDA margins back to 14%, two Rs 1,000 crore brands built in a decade (something no other Indian FMCG company has done), zero debt, Rs 1,100 crore of cash and investments, and the cheapest valuation among growth-priced consumer peers at 5.5x sales. The FY25 Project Neev episode, a Rs 63 crore inventory correction that produced a quarterly loss and a 20% single-day crash, reads in hindsight as the painful rebuild of a distribution system that now delivers: general trade and modern trade each grew 40%+ in Q1 FY27 across roughly 3 lakh outlets.
The risks are real and should be priced, not wished away. Mamaearth is still about 58% of revenue. Ad spend at roughly 32% of revenue is 3x a legacy FMCG player, so profitability remains hostage to marketing efficiency. HUL just bought Minimalist, Honasa's most direct rival in actives, and will now aim 9 million outlets of distribution at The Derma Co. But at Rs 427.90, 16% below the 52-week high, with the street having flipped from Sell to Buy in nine months, the risk-reward favors the business that proved it can take a punch.
How did Honasa Consumer start?
Varun Alagh spent nine years as a brand manager at Hindustan Unilever, Diageo, and Coca-Cola before quitting to found Honasa in 2016 with Ghazal Alagh. The insight was personal: after their son's birth they could not find toxin-free baby care in India and had to import it from the US. Mamaearth launched that December with six baby-care SKUs as Asia's first MadeSafe-certified personal care brand, sold Amazon-first with influencer-seeded marketing. Funding ran from a $125K Fireside seed to a $52M unicorn round at $1.2B in January 2022, the first unicorn of that year, and an IPO in November 2023 at Rs 324. The house-of-brands vision was already in the January 2020 Series B announcement: "Our vision is to create the FMCG conglomerate of the future."
What brands does Honasa own, and how does the flywheel work?
Mamaearth (Rs 1,000 cr+) is the flagship: the onion hair-care range, the Rice Dewy Bright face wash, and the Rosemary anti-hairfall shampoo are genuine ingredient franchises doing Rs 100 cr+ ARR each. The Derma Co crossed Rs 1,000 cr net-sales-value ARR in Q1 FY27, ten months faster than Mamaearth did, with three categories (serums, sunscreens, face cleansers) each above Rs 100 cr ARR. Aqualogica (Rs 180 cr+ ARR), Dr. Sheth's (Rs 150 cr+), BBlunt (Rs 100 cr), and newer bets (Reginald Men at Rs 150 cr ARR, FIKN fragrances, Lumineve prestige skincare) fill the shelf. Two failures show portfolio discipline: Ayuga sunset in June 2024 and Momspresso exited pre-IPO.
The flywheel is playbooks, not just brands: a consumer-insight engine, a content and influencer engine (6,900+ influencers), in-house R&D, asset-light third-party manufacturing, and one distribution pipe that carries every brand. The doctrine is build-first, buy-to-fill-gaps.
What do Honasa's financials show? (hypergrowth, crisis, recovery)
Revenue went from Rs 17 cr (FY19) to Rs 2,392 cr (FY26, +15.7%), with EBITDA at Rs 231 cr (9.7%) and PAT at Rs 200 cr (+175%). Q1 FY27 delivered record numbers: Rs 756 cr revenue (+27%), 14.1% EBITDA margin, Rs 90.5 cr PAT (+119%). The FY24-FY25 arc matters: FY24 was the margin inflection (EBITDA 1.5% to 7.1%), Q2 FY25 produced a Rs 18.6 cr net loss on the Rs 63 cr Neev inventory hit, and FY26 was the sharp recovery (9.7%, accelerating to 14.1%). Gross margin has barely moved in five years (69.7-70.2%): Honasa is a gross-margin compounder, not an expander. Ad intensity has declined for five straight quarters to 31.8% as offline and quick-commerce mix rose.
Who does Honasa compete with?
Honasa is winning online and contested everywhere else. Mamaearth leads digital-first baby care among urban millennial parents but is structurally capped in mass general trade where Himalaya, Johnson's, Dabur Baby, and Emami's BoroPlus FromMaa compete. The escalation that matters: HUL completed its Minimalist acquisition in April 2025 (90.5% at Rs 2,955 cr EV), giving Honasa's most direct actives rival 9 million outlets of distribution. Nykaa raised Dot & Key to 90% in September 2024. The April 2025 HUL Lakme "SPF Lie Detector" campaign, settled after the Delhi High Court called it "clearly disparaging," shows the battle for actives is now a litigated one. Quick commerce, projected to capture 40% of beauty category salience by 2030 per cited management commentary, favors assortment breadth where incumbents have structural edges.
Who runs Honasa, and is governance clean?
Varun Alagh is a career brand builder with a genuine scaling record and ownership of the Neev mistake followed by a sharp recovery. Ghazal Alagh drives the product engine. The board has 3 independents of 6, EY issued an unmodified FY25 opinion, and the Dubai distributor dispute was resolved in Honasa's favor (May-June 2026). Yellow flags: the CMO resigned in May 2025, there is no external CEO or COO (key-man risk), and about 1.5% of equity is pledged. Varun Alagh bought Rs 50 cr more stock in December 2025, a genuine signal.
What is Honasa worth? (valuation and scenarios)
At Rs 427.90: TTM P/E 56x, P/S 5.5x, EV/EBITDA ~44x. Honasa sits between legacy FMCG (Emami 22x, Dabur 34x) and Nykaa (357x), roughly in line with Marico and Tata Consumer on earnings, but the cheapest of the growth-priced set on sales. The discount reflects lower margins (9.7% vs 17-18% at Dabur/Marico) and a shorter track record, offset by far faster growth. Street: Jefferies Buy Rs 650, Emkay Buy Rs 550, CLSA Hold Rs 505.
FY2029 scenarios (328M shares, off FY26 reported revenue of Rs 2,392 cr): bear Rs 310 (12% CAGR, 9% EBITDA margin, 30x exit), base Rs 565 (18% CAGR, 11.5% margin, 38x), bull Rs 890 (24% CAGR, 13.5% margin, 45x). The base case implies ~Rs 11 EPS in FY29, so Rs 565 is ~51x FY29E earnings: a growth-compounder multiple mid-transition.
What are the key risks for Honasa?
Mamaearth concentration (~58% of revenue), ad-spend dependence (~32% of revenue), the HUL-Minimalist assault, ASCI green-claim guidelines on "toxin-free" positioning, mandate creep into men's grooming and nutraceuticals, and FY26 operating cash flow trailing PAT (0.7x) on a working-capital swing. The one-line watch: The Derma Co's share against Minimalist, ad-intensity trend, and OCF-to-PAT recoupling.
© 2026 DalalBytes Research · For educational purposes only. Not investment advice.